The Goldman Sachs Group Upgrades TG Therapeutics (NASDAQ:TGTX) to "Hold"

The Goldman Sachs Group upgraded shares of TG Therapeutics (NASDAQ:TGTX - Free Report) to a hold rating in a research report sent to investors on Thursday morning, Marketbeat reports. They currently have $37.00 target price on the biopharmaceutical company's stock.

TG Therapeutics Trading Down 1.4%

TGTX traded down $0.53 during trading on Thursday, reaching $37.14. 509,408 shares of the company's stock were exchanged, compared to its average volume of 2,881,068. TG Therapeutics has a one year low of $16.65 and a one year high of $46.48. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $5.90 billion, a PE ratio of 155.08 and a beta of 1.91. The firm has a fifty day moving average price of $36.18 and a two-hundred day moving average price of $35.25.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The firm's revenue for the quarter was up 90.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.07) EPS. As a group, equities research analysts forecast that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Activity

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director owned 228,816 shares in the company, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC raised its holdings in TG Therapeutics by 9.8% during the first quarter. Voya Investment Management LLC now owns 300,453 shares of the biopharmaceutical company's stock worth $11,847,000 after buying an additional 26,714 shares during the last quarter. Cim Investment Management Inc. acquired a new position in TG Therapeutics during the first quarter worth $241,000. Strs Ohio bought a new stake in shares of TG Therapeutics in the 1st quarter worth $785,000. Intech Investment Management LLC grew its stake in shares of TG Therapeutics by 20.5% in the 1st quarter. Intech Investment Management LLC now owns 86,527 shares of the biopharmaceutical company's stock worth $3,412,000 after acquiring an additional 14,694 shares in the last quarter. Finally, Focus Partners Wealth grew its stake in shares of TG Therapeutics by 4.1% in the 1st quarter. Focus Partners Wealth now owns 59,017 shares of the biopharmaceutical company's stock worth $2,327,000 after acquiring an additional 2,323 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.